GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (CHIX:COPNz) » Definitions » Cost of Goods Sold

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Cost of Goods Sold : CHF19.9 Mil (TTM As of Jun. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Cosmo Pharmaceuticals NV Cost of Goods Sold?

Cosmo Pharmaceuticals NV's cost of goods sold for the six months ended in Jun. 2023 was CHF18.4 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2023 was CHF19.9 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cosmo Pharmaceuticals NV's Gross Margin % for the six months ended in Jun. 2023 was 56.78%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Cosmo Pharmaceuticals NV's Inventory Turnover for the six months ended in Jun. 2023 was 1.50.


Cosmo Pharmaceuticals NV Cost of Goods Sold Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV Cost of Goods Sold Chart

Cosmo Pharmaceuticals NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.07 10.10 11.29 15.76 18.52

Cosmo Pharmaceuticals NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.09 1.40 17.66 1.52 18.41

Cosmo Pharmaceuticals NV Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF19.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cosmo Pharmaceuticals NV  (CHIX:COPNz) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cosmo Pharmaceuticals NV's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(42.592 - 18.409) / 42.592
=56.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Cosmo Pharmaceuticals NV's Inventory Turnover for the six months ended in Jun. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Cosmo Pharmaceuticals NV Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description

Traded in Other Exchanges
Address
Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (CHIX:COPNZ) Headlines

No Headlines